Source comparison
MK-677 Side Effects: Ghrelin-Mediated vs GH-Mediated
The side effect profile of MK-677 reflects its dual action as both a ghrelin agonist and a GH secretagogue. Appetite stimulation. The most commonly reported effect. Is ghrelin-mediated and occurs within 30–60 minutes of oral administration. This is mechanistic
This comparison does not assign a generated winner or score.
- The side effect profile of MK-677 reflects its dual action as both a ghrelin agonist and a GH secretagogue. Appetite stimulation. The most commonly reported effect. Is ghrelin-mediated and occurs within 30–60 minutes of oral administration. This is mechanistically distinct from the appetite suppression seen with GLP-1 agonists or the neutral hunger signaling of exogenous GH. In clinical trials, subjects reported increased hunger in 65% of cases, with mean caloric intake increases of 18–22% when food was provided ad libitum. Researchers managing body composition protocols typically address this by scheduling MK-677 administration during fasting windows or immediately before planned meals.
- Transient fluid retention and mild peripheral edema occur in approximately 25–35% of subjects, typically manifesting in the first 2–4 weeks of administration. This is GH-mediated. Elevated growth hormone increases sodium retention in renal tubules and shifts the balance between intravascular and interstitial fluid compartments. The effect is dose-dependent and usually resolves as the body adapts to chronically elevated GH levels, though it may persist at higher doses (≥50mg daily). Unlike the severe edema sometimes seen with supraphysiological exogenous GH, MK-677-induced water retention is generally mild and does not require diuretic intervention.
- Glucose metabolism changes warrant monitoring in extended protocols. MK-677 produces a transient increase in fasting blood glucose (mean elevation 5–8 mg/dL) and a modest reduction in insulin sensitivity during the first 8–12 weeks of use. A study published in Diabetes Care found that HbA1c increased by an average of 0.3% in non-diabetic subjects after 12 months of MK-677 use. Clinically insignificant in healthy populations but meaningful in subjects with pre-existing insulin resistance. The mechanism involves GH-stimulated lipolysis increasing circulating free fatty acids, which compete with glucose for cellular uptake via the Randle cycle. Subjects with baseline fasting glucose above 100 mg/dL should be excluded from research protocols or monitored with weekly glucose measurements during titration.